Jiahui Xu1,2, Honggui Li3, Ying Lv2, Chang Zhang4, Yiting Chen5, Dezhao Yu1. 1. Department of Pediatrics, Guangdong Second Hospital of Traditional Chinese Medicine, No. 60 Hengfu Road, 510000, Guangzhou, Guangdong, China. 2. Department of Pediatrics, The Fifth Clinical College of Guangzhou University of Traditional Chinese Medicine, 510000, Guangzhou, Guangdong, China. 3. Department of Pediatrics, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, 510000, Guangzhou, Guangdong, China. 4. Department of Internal Medicine, Guangdong Second Hospital of Traditional Chinese Medicine, 510000, Guangzhou, Guangdong, China. 5. Department of Pediatrics, The Affiliated Zhujiang Hospital of Southern Medical University, 510000, Guangzhou, Guangdong, China.
Abstract
BACKGROUND: Emerging evidence shows that long noncoding RNA (lncRNA) has been a novel insight in various diseases, including pneumonia. Even though lncRNA X-inactive-specific transcript (XIST) is well studied, its role in pneumonia remains to be largely unrevealed. METHODS: Expression of XIST, miRNA-30b-5p (miR-30b-5p), and CC chemokine ligand 16 (CCL16) was detected using reverse transcriptase quantitative polymerase chain reaction and western blotting; their interaction was confirmed by dual-luciferase reporter assay. Apoptosis, inflammation, and toll-like receptor 4 (TLR4)/NF-κB signaling pathway were measured using methyl thiazolyl tetrazolium assay, flow cytometry, western blotting, and enzyme-linked immunosorbent assay. RESULTS: Lipopolysaccharide (LPS) stimulation decreased cell viability and B cell lymphoma (Bcl)-2 expression, and increased cell apoptosis rate and expression of Bcl-2-associated X protein (Bax), cleaved-caspase-3, interleukin (IL)-6, IL-1β, and tumor necrosis factor α (TNF-α) in WI-38 cells. Expression of XIST and CCL16 was upregulated in the serum of patients with pneumonia and LPS-induced WI-38 cells, respectively; silencing XIST and CCL16 could suppress LPS-induced apoptosis and inflammation in WI-38 cells, and this protection was abolished by miR-30b-5p downregulation. Moreover, XIST and CCL16 could physically bind to miR-30b-5p, and XIST regulated CCL16 expression via sponging miR-30b-5p. TLR4 and phosphorylated P65 (p-P65) and p-IκB-α were highly induced by LPS treatment, and this upregulation was diminished by blocking XIST, accompanied with CCL16 downregulation and miR-30b-5p upregulation. CONCLUSIONS: Silencing XIST could alleviate LPS-induced inflammatory injury in human lung fibroblast WI-38 cells through modulating miR-30b-5p/CCL16 axis and inhibiting TLR4/NF-κB signaling pathway.
BACKGROUND: Emerging evidence shows that long noncoding RNA (lncRNA) has been a novel insight in various diseases, including pneumonia. Even though lncRNA X-inactive-specific transcript (XIST) is well studied, its role in pneumonia remains to be largely unrevealed. METHODS: Expression of XIST, miRNA-30b-5p (miR-30b-5p), and CC chemokine ligand 16 (CCL16) was detected using reverse transcriptase quantitative polymerase chain reaction and western blotting; their interaction was confirmed by dual-luciferase reporter assay. Apoptosis, inflammation, and toll-like receptor 4 (TLR4)/NF-κB signaling pathway were measured using methyl thiazolyl tetrazolium assay, flow cytometry, western blotting, and enzyme-linked immunosorbent assay. RESULTS: Lipopolysaccharide (LPS) stimulation decreased cell viability and B cell lymphoma (Bcl)-2 expression, and increased cell apoptosis rate and expression of Bcl-2-associated X protein (Bax), cleaved-caspase-3, interleukin (IL)-6, IL-1β, and tumor necrosis factor α (TNF-α) in WI-38 cells. Expression of XIST and CCL16 was upregulated in the serum of patients with pneumonia and LPS-induced WI-38 cells, respectively; silencing XIST and CCL16 could suppress LPS-induced apoptosis and inflammation in WI-38 cells, and this protection was abolished by miR-30b-5p downregulation. Moreover, XIST and CCL16 could physically bind to miR-30b-5p, and XIST regulated CCL16 expression via sponging miR-30b-5p. TLR4 and phosphorylated P65 (p-P65) and p-IκB-α were highly induced by LPS treatment, and this upregulation was diminished by blocking XIST, accompanied with CCL16 downregulation and miR-30b-5p upregulation. CONCLUSIONS: Silencing XIST could alleviate LPS-induced inflammatory injury in human lung fibroblast WI-38 cells through modulating miR-30b-5p/CCL16 axis and inhibiting TLR4/NF-κB signaling pathway.
Authors: Miaotian Cai; Francesco Bonella; Xuan He; Stephan U Sixt; Rafael Sarria; Josune Guzman; Ulrich Costabel Journal: Respir Med Date: 2013-07-05 Impact factor: 3.415
Authors: T Pannellini; M Iezzi; E Di Carlo; E Eleuterio; A Coletti; A Modesti; S Rosini; M Neri; P Musiani Journal: Int J Immunopathol Pharmacol Date: 2004 May-Aug Impact factor: 3.219
Authors: A Arakelyan; E Kriegova; Z Kubistova; F Mrazek; M Kverka; R M du Bois; V Kolek; M Petrek Journal: Clin Exp Immunol Date: 2009-03 Impact factor: 4.330
Authors: Christine Winter; Katharina Taut; Mrigank Srivastava; Florian Länger; Matthias Mack; David E Briles; James C Paton; Regina Maus; Tobias Welte; Michael D Gunn; Ulrich A Maus Journal: J Immunol Date: 2007-05-01 Impact factor: 5.422
Authors: Sterghios A Moschos; Andrew E Williams; Mark M Perry; Mark A Birrell; Maria G Belvisi; Mark A Lindsay Journal: BMC Genomics Date: 2007-07-17 Impact factor: 3.969
Authors: Marco Antonio Barajas-Mendiola; María Guadalupe Salgado-Lora; Joel Edmundo López-Meza; Alejandra Ochoa-Zarzosa Journal: Front Microbiol Date: 2022-09-23 Impact factor: 6.064